Primary aldosteronism and lower-extremity arterial disease: a two-sample Mendelian randomization study
Authors' conclusion
Primary aldosteronism is genetically and causally associated with higher risks of LEAD and gangrene, especially among patients with diabetes. Targeting on the autonomous aldosterone secretion may prevent LEAD progression.
Study context
- Population
- UK Biobank participants with and without diabetes39,713 with DM
- Comparison
- Higher vs lower genetically predicted primary aldosteronism (PA)
- Outcome
- LEAD and LEAD-related gangrene or amputation
Methodological detailspolygenic risk score, UK Biobank
- Polygenic risk score
- UK Biobank
Performance
As reported in the abstract
LEAD, gangrene and amputation among patients with DM (third vs first tertile of PA PRS)
Third tertile of PA PRS vs First tertile of PA PRSOdds ratio (95% CI)
LEAD, patients with DM
1.24(1.03–1.49)
Gangrene, patients with DM
2.09(1.27–3.44)
Amputation, patients with DM
1.72(1.10–2.67)
Further findings
Two-sample Mendelian randomization: genetically predicted PA and lower-extremity arterial disease (LEAD), gangrene
- Inverse variance weighted OR for LEAD
- 1.20 (95% CI 1.08-1.34)
- Inverse variance weighted OR for gangrene
- 1.48 (95% CI 1.28-1.70)
- No evidence of significant heterogeneity or directional pleiotropy
Original publication
Primary aldosteronism and lower-extremity arterial disease: a two-sample Mendelian randomization study. Cardiovasc Diabetol. Published 20 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →